A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: Characterization of infliximab-resistant cases and PK-based modified therapy

Modern Rheumatology

Volumn 17, Issue 2, 2007, Pages 83-91

  Mori, Shunsuke ^a  

^a NHO Kumamoto Saishunsou National Hospital   (Japan)

Author keywords

Infliximab; Pharmacokinetics; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; PREDNISONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MONOTHERAPY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; THERAPY RESISTANCE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34247179007     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-006-0544-9     Document Type: Article

References (28)

1. JC Beckham DS Caldwell BL Peterson AM Pippen MS Currie FJ Keefe 1992 Disease severity in rheumatoid arthritis: Relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures J Clin Immunol 12 353-61 1430106 10.1007/BF00920793 1:STN:280:ByyD2MrivFE%3D
2. CQ Chu M Field M Feldmann RN Maini 1991 Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis Arthritis Rheum 34 1125-32 1930331 10.1002/art.1780340908 1:STN:280:By2D38bht1c%3D
3. PE Lipsky DM van der Heijde EW St Clair DE Furst FC Breedveld JR Kalden 2000 Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 343 1594-602 11096166 10.1056/NEJM200011303432202 1:CAS:528:DC%2BD3cXovVeltLk%3D
4. EW St Clair DM van der Heijde JS Smolen RN Maini JM Bathon P Emery 2004 Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial Arthritis Rheum 50 3432-43 15529377 10.1002/art.20568 1:CAS:528:DC%2BD2cXhtVOqtrvJ
5. L Klareskog D van der Heijde JP de Jager A Gough J Kalden M Malaise 2004 Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial Lancet 363 675-81 15001324 10.1016/S0140-6736(04)15640-7 1:CAS:528:DC%2BD2cXhs12jur4%3D
6. FC Breedveld MH Weisman AF Kavanaugh SB Cohen K Pavelka R van Vollenhoven 2006 The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 26-37 16385520 10.1002/ art.21519 1:CAS:528:DC%2BD28XhsVens74%3D
7. JJ Gomez-Reino L Carmona 2006 Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period Arthritis Res Ther 8 R2916507128 10.1186/ar1881
8. KE Hansen JP Hildebrand MC Genovese JJ Cush S Patel DA Cooley 2004 The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis J Rheumatol 31 1098-102 15170921 1:CAS:528:DC%2BD2cXlsFWgtrY%3D
9. MC Wick S Ernestam S Lindblad J Bratt L Klareskog RF van Vollenhoven 2005 Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): Results from the STURE registry at Karolinska University Hospital Scand J Rheumatol 34 353-8 16234182 10.1080/03009740510026887 1:CAS:528:DC%2BD2MXht1GhtLzF
10. JM van den Brande H Braat GR van den Brink HH Versteeg CA Bauer I Hoedemaeker 2003 Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease Gastroenterology 124 1774-85 12806611 10.1016/S0016-5085(03)00382-2 1:CAS:528:DC%2BD3sXlt1yrt7Y%3D
11. A Di Sabatino R Ciccocioppo B Cinque D Millimaggi R Morera L Ricevuti 2004 Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease Gut 53 70-7 14684579 10.1136/gut.53.1.70 1:CAS:528:DC%2BD2cXptlKqsQ%3D%3D
12. F Wolfe DJ Hawley 1998 The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients J Rheumatol 25 2108-17 9818651 1:STN:280:DyaK1M%2Fjtl2lsg%3D%3D
13. AI Catrina C Trollmo E af Klint M Engstrom J Lampa Y Hermansson 2005 Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report Arthritis Rheum 52 61-72 15641091 10.1002/art.20764 1:CAS:528:DC%2BD2MXht1Kisb4%3D
14. I Nestorov 2005 Clinical pharmacokinetics of tumor necrosis factor antagonists J Rheumatol Suppl 74 13-8 15742459 1:CAS:528:DC%2BD2MXivVynsrs%3D
15. S Mori F Imamura C Kiyofuji K Ito Y Koga I Honda 2006 Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody Mod Rheumatol 16 58-62 16622728 10.1007/ s10165-005-0454-2
16. S Mori F Imamura C Kiyofuji M Sugimoto 2006 Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody Mod Rheumatol 16 251-5 16906378 10.1007/s10165-006-0491-5
17. EW St Clair CL Wagner AA Fasanmade B Wang T Schaible A Kavanaugh 2002 The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 46 1451-9 12115174 10.1002/art.10302 1:CAS:528:DC%2BD38Xltlantbc%3D
18. ML Prevoo MA van't Hof HH Kuper MA van Leeuwen LB van de Putte PL van Riel 1995 Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 38 44-8 7818570 10.1002/art.1780380107 1:STN:280:ByqC3MfjvFI%3D
19. N Miyasaka T Takeuchi K Eguchi 2005 Official Japanese guidelines for the use of infliximab for rheumatoid arthritis Mod Rheumatol 15 4-8 17028815 10.1007/s10165-004-0357-7 1:CAS:528:DC%2BD2MXhsV2is7k%3D
20. FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper 1988 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315-24 3358796 10.1002/art.1780310302 1:STN:280:BieC1M3nt1Q%3D
21. DT Felson JJ Anderson M Boers C Bombardier D Furst C Goldsmith 1995 American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 38 727-35 7779114 10.1002/ art.1780380602 1:STN:280:ByqB1MfgsFI%3D
22. RN Maini FC Breedveld JR Kalden JS Smolen D Davis JD Macfarlane 1998 Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1552-63 9751087 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W 1:CAS:528:DyaK1cXmsVChtbg%3D
23. AF LoBuglio RH Wheeler J Trang A Haynes K Rogers EB Harvey 1989 Mouse/ human chimeric monoclonal antibody in man: Kinetics and immune response Proc Natl Acad Sci USA 86 4220-4 2726771 10.1073/pnas.86.11.4220 1:CAS:528:DyaL1MXksFGnsbc%3D
24. DM Knight H Trinh J Le S Siegel D Shealy M McDonough 1993 Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Mol Immunol 30 1443-53 8232330 10.1016/0161-5890(93)90106-L 1:CAS:528:DyaK2cXivFSisw%3D%3D
25. RF van Vollenhoven S Brannemark L Klareskog 2004 Dose escalation of infliximab in clinical practice: Improvements seen may be explained by a regression-like effect Ann Rheum Dis 63 426-30 15020338 10.1136/ ard.2003.010967 1:CAS:528:DC%2BD2cXjs1ahs7o%3D
26. CL Wagner A Schantz E Barnathan A Olson MA Mascelli J Ford 2003 Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade Dev Biol (Basel) 112 37-53 1:CAS:528:DC%2BD3sXpslGms78%3D
27. S Pavy A Constantin T Pham L Gossec JF Maillefert A Cantagrel 2006 Methotrexate therapy for rheumatoid arthritis: Clinical practice guidelines based on published evidence and expert opinion Joint Bone Spine 73 388-95 16626993 10.1016/j.jbspin.2006.01.007 1:CAS:528:DC%2BD28XptVKjtL0%3D
28. MP Curran CM Perry 2005 Tacrolimus: In patients with rheumatoid arthritis Drugs 65 993-1001 15892590 10.2165/00003495-200565070-00005 1:CAS:528:DC%2BD2MXltlKqsbs%3D discussion 2-3